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Abstract
Background: Energy and Zinc (Zn) deficiencies have been associated with nutritional related
growth retardation as well as growth hormone (GH) resistance. In this study, the relationship
between suboptimal energy and/or Zn intake and growth in rats and their response to
immunoreactive exogenous recombinant human GH (GHi), was determined.
Results: Rats treated with GHi and fed ad-libitum energy and Zn (100/100) had increased IGFBP-
3 (p < 0.05) as compared with NSS (215 ± 23 vs. 185 ± 17 ng/ml) along with similar body weight
gain. Rats treated with GHi and fed suboptimal energy and full Zn (70/100) had significantly
increased weight gain (109.0 ± 18.2 vs. 73.8 ± 11.0 g) and serum IGF-I levels (568 ± 90 vs. 420 ±
85 ng/ml), along with decreased total body water (TBW; 61.0 ± 1.6 vs. 65.7 ± 2.1%) as compared
to NSS controls. However, body weight gain was reduced (p < 0.05) as compared with rats fed ad-
libitum energy. Growth hormone treated rats fed only suboptimal Zn (100/70), had increased
weight gain (217.5 ± 13.2 vs. 191.6 ± 17.9 g; p < 0.05) compared to those given NSS. These rats
gained weight in similar amounts to those fed full Zn. Rats treated with GHi and fed both
suboptimal energy and Zn (70/70) showed similar results to those fed suboptimal energy with
appropriate Zn (70/100), along with significant increases in IGFBP-3 levels (322 ± 28 vs. 93 ± 28 ng/
ml). All restricted rats had reduced 24-h EE (kcal/100 g BW) and physical activity index (oscillations/
min/kg BW) and GHi did not overcome these effects.
Conclusion: These results suggest that GHi enhances weight gain in rats with suboptimal energy
and Zn intake but does not modify energy expenditure or physical activity index. Suboptimal Zn
intake did not exacerbate the reduced growth or decrease in energy expenditure observed with
energy restriction.
Introduction
Nutritional growth retardation or nutritional dwarfing
(ND) denotes a linear growth deterioration accompanied
by inadequate weight gain [1]. It has been associated with
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short stature since growth deceleration represents an
adaptive response to suboptimal nutrition. In the United
States, ND is frequently associated with self imposed diet-
ing due to fear of obesity and/or hypercholesterolemia,
extreme exercise and eating disorders, among many other
reasons [2-4]. In contrast to more severe forms of malnu-
trition observed worldwide, ND is manifested by a height-
for-age deficit while both weight-for-height and standard
biochemical nutritional indexes remain within normal
limits [1]. Several reports have also demonstrated reduced
Insulin-like Growth Factor-1 (IGF-I) level and decreased
erythrocyte Na+K+-ATPase activity during suboptimal
energy intake [5-9]. The degree of energy restriction por-
trays one of the most important factors related with
growth hormone (GH) action. Consequently, elevated
GH level along with reduced IGF-I, Insulin-like Growth
Factor Binding Protein-3 (IGFBP-3) and Insulin levels
have been described in both human and animal research
as a consequence of starvation [10-18]. Furthermore,
attenuated spontaneous GH secretion has also been
reported in patients with ND during puberty [19]. How-
ever, utilizing an animal model of suboptimal nutrition,
it has been reported that GH effects are feasible during
mild energy restriction by administering exogenous GHi
[20,21].
Although adequate energy intake plays a major role affect-
ing growth, micronutrients like Zn have also demon-
strated to be essential regulators of growth and GH action
[22-24]. Profound Zn deficiency with adequate energy
intake has been frequently associated with growth failure
and delayed sexual maturation, affecting cell division,
DNA, RNA and protein synthesis [25,26]. Zinc deficiency
also reduces the level of liver GH receptors, serum IGF-I,
GH binding proteins and both mRNA's for GH receptors
and IGF-I [24,26]. Furthermore, binding of Zn in cultured
rat hepatocytes with a Zn chelator DTPA (diethylenetri-
aminepenta-acetic acid) did not reduce mRNAs for IGF-I,
GH receptors or GH binding proteins while metal-
lothionein gene expression was strongly inhibited. There-
fore, the decline in IGF-I associated with in vivo Zn
deficiency did not appear to be due to changes in extracel-
lular Zn concentration at the hepatocyte level [27]. Often
Zn deficiency is associated with reduced energy intake
[28,29] and the effects of each one of these nutritional
alterations alone, or in combination with each other is
not known. Furthermore, the effects of GHi administra-
tion in rats with experimentally induced suboptimal
energy with and without decreased Zn intakes have not
been elucidated.
In this paper we report the effects of exogenous GHi
administration in an animal model of suboptimal nutri-
tion where energy and/or Zn intake was decreased by 30%
of requirements [5,20,21]. Our goal was to determine if
exogenous GHi administration would attenuate the detri-
mental effects of mild restrictions of energy and Zn indi-
vidually or in combination with each other. Furthermore,
we hypothesized that energy expenditure and physical
activity would be reduced with mild nutrient restrictions.
This was determined utilizing a new Enhanced Metabolic
Testing Activity Chamber.
Results
Effects of GHi on weight gain
All rats were healthy throughout the experiment without
any apparent illness or weight loss. The effects of GHi
administration (solid lines) versus NSS administration
(dotted lines) for each dietary group are shown in Figures
3, 4, 5, 6.
No significant differences were found in body weight gain
between the GHi treated and the NSS control group rats
fed 100% energy/100% Zn (Diet A) (Figure 3). However,
rats fed 70% energy/100% Zn (Diet B) and treated with
GHi showed significantly (p < 0.05) increased weight gain
over the four week experimental period as compared with
their respective NSS controls. The differences in body
weight gain became apparent after the first week of the
study (Figure 4). However, the rats in this group fed
restricted energy and full Zn gained less weight than the
rats fed energy and Zn ad-libitum (Diet A) regardless of
GHi treatment. Similarly growth hormone administration
produced a response in the group fed 100% energy/ 70%
Zn (Diet C) were GHi treated rats gained significantly (p
< 0.05) more weight than their respective NSS controls
(Figure 5). The differences became apparent after the sec-
ond week of the study. However, the overall weight gain
of the rats in this group fed restricted amounts of Zn and
a full energy complement was similar to those in the
group fed energy and Zn ad-libitum (100% energy/100%
Zn; Diet A) regardless of GHi treatment. Finally, when
both energy and Zn intake were reduced to 70% energy/
70% Zn (Diet D), rats treated with GHi gained signifi-
cantly (p < 0.05) more weight than their respective NSS
controls (Figure 6). Weight gain differences became
apparent after the first week of the study. The weight gain
of the rats in this group was similar to that found for rats
restricted to 70% of the ad-libitum energy intake with full
Zn intake (Diet B).
Effects of GHi on IGF-I, IGFBP-3 and insulin levels
The hormonal pattern at the end of the study is shown in
Table 3. When rats were fed 100% energy/100% Zn (Diet
A) and treated with GHi, IGFBP-3 increased significantly
(p < 0.05) versus those rats given NSS. In comparison to
the NSS treated rats, treatment with GHi increased serum
IGF-I in both groups of rats fed 70% ad-libitum energy
with or without Zn restriction (Diets B and D). Further-
more, serum IGFBP-3 increased in the GHi-treated groupNutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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when both energy and Zn intake were reduced to 70%.
However, serum IGFBP-3 did not differ among GHi-
treated rats fed at 70% of energy intake and 100% of Zn.
Additionally, no significant differences were found in
serum IGFBP-3 when energy was maintained at 100%.
Serum insulin did not change significantly in GHi treated
rats as compared to controls.
Metabolic changes associated with caloric restriction
In comparison to rats administered NSS, GHi administra-
tion had no effects on 24-hour energy expenditure and the
index of physical activity within any of the dietary treat-
ments (Table 4). However, the RQ was lower in GHi
treated rats fed 70% of ad-libitum energy intake. Energy
expenditure (p < 0.05) and physical activity index (p <
0.05) were reduced in all restricted groups as compared
with all those fed a full complement of energy. The reduc-
tion in energy expenditure was from 19.5 ± 2.9 to 16.9 ±
1.9 kcal/100 g body weight while the reduction in the
physical activity index was from 2.5 ± 0.5 to 2.1 ± 0.3
oscillations/min/kg body weight. Mild Zn restriction did
not further reduce these parameters below those found for
the energy restricted groups. Similarly, GHi administra-
tion did not overcome the reduced energy expenditure
and physical activity index found in the energy restricted
rats.
Effects of GHi on body composition
Body composition analysis is shown in Table 5. There
were no significant differences in FFM and BF between the
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares,  interrupted line) fed a 1:1 carbohydrate to fat purified diet with 100% of the energy and 100% of the zinc requirement for rats Figure 3
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares, 
interrupted line) fed a 1:1 carbohydrate to fat purified diet with 100% of the energy and 100% of the zinc requirement for rats. 
* = significant difference (p < 0.05) for that particular week.Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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GHi and NSS groups regardless of dietary treatment. How-
ever, compared to their respective NSS controls, rats
treated with GHi and fed either energy restricted diet, with
our without Zn deficiency (Diets B and D), showed signif-
icant (p < 0.05) reductions in TBW.
Discussion
The experimental animal model of suboptimal nutrition
allowed the independent assessment of suboptimal intake
of specific nutrients and the effects of administered exog-
enous GHi. At the same time we were able to determine
the effects of administered GHi under these conditions. In
this study different conditions of suboptimal nutrition in
rats were assessed by limiting dietary energy and/or zinc
intakes to 70% of ad-libitum. This was possible by utiliz-
ing purified diets which allowed us to provide a precise
amount of all nutrients, including Zn, which might not
have been possible with commercial rat chows. Further-
more, this also permits determination of the effects of
rhGH administration on 24-hour energy expenditure and
on the index of physical activity utilizing an established
rodent model of suboptimal nutrition, which has never
been studied before. The data showed that exogenous
recombinant human growth hormone enhanced body
weight gain and increased serum IGF-I levels in energy
restricted rats. Furthermore, serum IGFBP-3 levels were
also increased during simultaneous suboptimal energy
and zinc restriction. However, suboptimal zinc restriction
alone did not interfere with body weight gain or exacer-
bate any of the detrimental effects of specific suboptimal
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares,  interrupted line) fed a 1:1 carbohydrate to fat purified diet with 70% of the energy and 100% of the zinc requirement for rats Figure 4
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares, 
interrupted line) fed a 1:1 carbohydrate to fat purified diet with 70% of the energy and 100% of the zinc requirement for rats. * 
= significant difference (p < 0.05) for that particular week.Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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energy restriction. Moreover, GHi treatment reduced the
amount of total body water in energy restricted rats.
Finally, a reduction in energy expenditure and the index of
physical activity were shown during suboptimal energy
intake and Zn restriction however, GHi treatment did not
enhance these parameters. The rat's physical activity was
not restricted in any way. The slightly smaller space pro-
vided by the Nalgene metabolic cage might have poten-
tially reduced the rat's spontaneous physical activity,
however this appeared not to affect the results. All rats had
metabolic measurements under the same conditions.
Decreased body gain was previously reported during mild
suboptimal energy intake in rats fed at 60 and 80% of ad-
libitum energy intake [5]. These findings showed that a
40% reduction in energy intake reduced weight gain by
61% of control levels over a four week period. When con-
sidering all of the rats fed the reduced energy diet in the
present study, regardless of treatment or Zn levels, a 30%
reduction in energy intake resulted in a 40% reduction in
body weight gain in comparison to all control animals.
It was previously found that GHi given to rats fed a
restricted diet (60% energy) resulted in increased cumula-
tive weight gain when compared to their NSS controls,
while IGF-I and IGFBP-3 levels were elevated [20]. Our
results confirm that GHi enhanced body weight gain by
>18% when rats were fed suboptimally (reduction by
30% in dietary energy). Body weight differences were
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares,  interrupted line) fed a 1:1 carbohydrate to fat purified diet with 100% of the energy and 70% of the zinc requirement for rats Figure 5
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares, 
interrupted line) fed a 1:1 carbohydrate to fat purified diet with 100% of the energy and 70% of the zinc requirement for rats. * 
= significant difference (p < 0.05) for that particular week.Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares,  interrupted line) fed a 1:1 carbohydrate to fat purified diet with 70% of the energy and 70% of the zinc requirement for rats Figure 6
Weekly weight gain for both growth hormone treated (filled dots, continued line) and normal saline control rats (filled squares, 
interrupted line) fed a 1:1 carbohydrate to fat purified diet with 70% of the energy and 70% of the zinc requirement for rats. * 
= significant difference (p < 0.05) for that particular week.
Table 3: Hormonal profile after mild energy and Zn restriction in rhGH treated rats
Energy/zinc (%) 100/100 70/100 100/70 70/70
rhGH1 NSS2 rhGH NSS rhGH NSS rhGH NSS
IGF-1 (ng/ml) 1012.5 ± 82.7 784.8 ± 231.3 568.4 ± 90.2* 420.3 ± 84.5 1089.5 ± 133.9 1074.1 ± 220.1 657.0 ± 114.1* 423.0 ± 139.9
IGFBP-3 (ng/ml) 214.5 ± 23.3* 184.7 ± 17.2 107.9 ± 35.5 96.9 ± 9.3 231.0 ± 36.0 201.0 ± 21.3 322.0 ± 28.4* 93.4 ± 28.0
Insulin (mIU/ml) 21.3 ± 7.6 52.7 ± 28.6 22.2 ± 12.6 39.5 ± 20.8 50.9 ± 14.4 71.4 ± 17.3 26.3 ± 6.6 17.1 ± 6.5
* = P < 0.05 between treatment groups
1 = Recombinant human growth hormone
2 = Normal saline solutionNutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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mainly associated to energy restriction. No body weight
differences were evident in Zn restricted rats as long as the
energy intake was appropriate.
Increments in IGF-I and IGFBP-3 serum concentrations
were clearly linked to the effects of GHi in energy
restricted rats. However, our data demonstrated no
differences in serum IGF-I and IGFBP-3 concentrations
with mild isolated Zn restriction. Thus, reduced Zn intake
influenced the action of GHi in IGF-I and IGFBP-3 serum
concentrations only when the energy intake was simulta-
neously restricted, suggesting no role for the suboptimal
intake of Zn. It is possible that reducing Zn to only 70%
of requirements, with adequate energy, is not enough to
cause any significant effects on the hormonal parameters
studied. It may be necessary to further reduce dietary Zn
before an effect on IGF-I or IGFBP-3 is observed. For
example, Zn deficiency in rats fed adequate energy grew
poorly and showed reduced serum IGF-I, GH receptor
numbers and GH binding proteins [26]. Furthermore,
gene expression for both IGF-I and GH receptors in rats
were reduced when fed a Zn deficient, adequate energy
diet [24].
Altogether, recombinant human growth hormone ther-
apy reduces carbohydrate utilization shifting all meta-
bolic loads to lipid metabolism [30,31]. Moreover,
physical activity, normal growth, dietary intake [31] and
GH itself have an essential role in body composition [32-
35]. For instance, the administration of GHi, promoting
lipid utilization, reduces total body fat. In our study our
partially energy restricted animals showed a slight
increase in body weight gain with GHi treatment. Moreo-
ver, we found a slight reduction in the respiratory quotient
with GHi administration in those rats on energy restricted
diets. This suggests that GHi treatment shifts the
metabolic load to lipogenesis, as has been found in a pre-
vious study [31,37]. Furthermore, GHi action was not
affected by restricted Zn intake as long as the energy intake
was not restricted.
The amount of GH administered may have variable effects
on body composition in rats. For example, investigators in
two previous studies found minimal changes in body fat
and fat-free mass in rats fed ad-libitum and administered
0.05 or 0.10 mg/100 g body weight of GHi daily [20,21].
This is suggestive that under ad-libitum or mild energy
restriction GHi treatment at or below 0.10 mg/100 g body
weight will not change the amount of fat-free mass
Table 4: Metabolic profile of rats after mild energy and zinc restriction
Energy/zinc (%) 100/100 70/100 100/70 70/70
Dietary treatment rhGH1 NSS2 rhGH NSS rhGH NSS rhGH NSS
24-EE2 (Kcal/100 g BW) 21.2 ± 2.4 19.6 ± 3.3 17.2 ± 1.5 16.4 ± 0.7 17.4 ± 3.4 19.8 ± 2.0 17.5 ± 2.8 16.5 ± 2.4
RQ3 (VCO2/VO2) 0.82 ± .02 0.89 ± .03 0.82 ± .08 0.89 ± .07 0.90 ± .09 0.81 ± .01 0.82 ± 0.1 0.91 ± 0.01
Physical activity4 2.6 ± 0.5 2.2 ± 0.2 2.0 ± 0.5 2.2 ± 0.1 2.3 ± 0.4 2.7 ± 0.8 2.3 ± 0.2 2.1 ± 0.3
1 = Recombinant human growth hormone
2 = Normal saline solution
3 = Twenty-four hour energy expenditure
4 = Respiratory quotient
5 = Oscillations/minute/kg body weight
Table 5: Body composition by carcass analysis after mild energy and zinc restriction.
Energy/zinc (%) 100/100 70/100 100/70 70/70
Dietary treatment GHi1 NSS2 GHi NSS GHi NSS GHi NSS
Body fat (%) 12.0 ± 1.3 12.8 ± 2.1 8.4 ± 2.6 8.3 ± 1.0 12.3 ± 1.4 12.6 ± 2.1 7.2 ± 1.0 8.8 ± 3.0
Fat-free mass (%) 88.0 ± 1.3 87.2 ± 2.2 91.6 ± 2.6 91.7 ± 1.0 88.1 ± 1.4 87.6 ± 0.9 92.8 ± 1.0 91.2 ± 3.0
Total Body water (%) 57.7 ± 3.3 60.3 ± 2.2 61.1 ± 1.6* 65.8 ± 2.1 57.3 ± 2.9 59.9 ± 1.6 58.8 ± 7.2* 66.6 ± 2.1
* = P < 0.05 between treatment groups
1 Immunoreactive recombinant human growth hormone
2 Normal saline solutionNutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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relative to body fat. It is possible that a higher dosage of
GHi will elicit these effects. For example, body fat
decreased significantly in similarly fed rats when adminis-
tered 0.35 mg/100 g body weight of GHi daily [37]. More-
over, the whole body carcass analysis methodology may
not be sensitive enough to detect subtle changes in body
fat in rats at the lower dosages of GHi used in this and in
similar studies [20,21]. This is further evidenced by the
lack of changes in energy expenditure and physical activity
index observed in rats fed either ad-libitum or energy
restricted diets and treated with 0.1 mg/100 g body weight
of GHi.
In this study energy restriction resulted in a reduction of
24-hour energy expenditure and physical activity index in
rats. Furthermore, these changes were not affected by GHi
treatment. This is suggestive that metabolic adaptations
occurred due to suboptimal energy intake. Others have
found similar metabolic and biochemical changes
associated with suboptimal energy intake. For example,
erythrocyte NaK-ATPase was reduced in children diag-
nosed with nutritional dwarfing, a form of suboptimal
nutrition that exists for a prolonged period of time [8].
Similar reductions in erythrocyte NaK-ATPase were also
found in rats fed energy restricted diets [5]. Moreover,
metabolic rate and physical activity were reduced when
rats were fed energy restricted diets [43]. The results of all
these studies [5,8,20,21,37] suggests that metabolic adap-
tations occur beginning with mild energy restriction.
Growth deceleration, subsequent growth failure and short
stature are the most remarkable consequences of persist-
ent suboptimal nutrition [1-5]. Although adequate energy
intake has a preponderant role affecting growth, many
other micronutrients play a meaningful role in growth
regulation and growth hormone action. Furthermore,
extensive animal and human research have already estab-
lished the association between energy restriction, severe
Zn deficiency and growth failure. Therefore, elevated
growth hormone levels, along with reduced IGF-I, IGFBP-
3 and insulin levels, have been described in severe energy
and Zn restrictions [10-18,22-26].
Malnourished humans have increased, whereas rats have
decreased serum levels of growth hormone [38].
Decreased growth-hormone levels in starved rats may be
caused by increased somatotropin-releasing inhibitory
hormone or by reduced stimulation of hypothalamic
somatotroph cells by growth-hormone-releasing hor-
mone [39]. Furthermore, serum leptin has been found to
play a role in the decline of growth hormone in rats [40].
However, serum insulin growth factor-1 (IGF-I) produc-
tion in starved rats remains sensitive to growth hormone
levels [41]. In previous studies we have validated the rat
model for testing various treatments during suboptimal
nutrition [5,20,21].
Growth retardation is the most predominant finding in
many of the conventional Zn deficiency studies [24-29].
However, limited information exists concerning the
effects of suboptimal Zn intake [42] and no one has inves-
tigated the effects of GHi administration during experi-
mental suboptimal Zn restriction. Thus, our study showed
GHi therapy promoting body weight gain despite subop-
timal Zn intake. Consequently, in contrast to most of
these studies involving severe Zn deficiency, our data sug-
gest a secondary role of Zn when Zn intake was only
restricted to 70% of daily requirements while maintaining
adequate energy intake. In addition to weight gain, other
GHi metabolic effects were also obtained, such as
increases in both IGF-I and IGFBP-3 levels, during Zn
restriction if associated with appropriate energy intake.
Our study results give us an idea of the role of Zn in
growth during mild malnutrition, which is not clearly
understood. The assessment of Zn status is hampered by
the lack of a single sensitive and specific biochemical fac-
tor [43]. Currently, the clinical method to assess Zn status
in children is to measure increase growth velocity in
response to Zn supplementation. Controversy exists
between studies, where positive effects of Zn supplemen-
tation have been found against no effects of supplementa-
tion. No effects were found in adolescents with ND and in
sub Saharan infants and young children [5,6,12-15] while
malnourished infants and children showed increased
growth [6-8]. Researchers have suggested that these differ-
ences may be attributed to the severity of Zn deficiency, to
the dose, frequency of dosing and age of the infants. It has
also been observed that in non-stunted infants, Zn sup-
plementation results in increased growth compared with
the control group, but with a less pronounced effect.
Therefore, researchers have concluded that beneficial
effects of Zn supplementation on growth are related to the
degree of stunting and of Zn deficiency. Furthermore, it
was suggested that Zn supplementation halted the
stunting process, due to improved appetite and decreased
episodes of gastrointestinal and respiratory disease, in
stunted infants in rural Ethiopia [44].
The amount and method of administration of growth hor-
mone, along with the type of feeding regime might cause
differences in anabolic responses. For example, healthy
normally fed rats injected with 20 micrograms daily of
recombinant human growth hormone at the sight of an
induced fracture for 10 days showed reduced healing
times without changes in bodyweight [45]. In another
study, 15 day slow release recombinant human growth
hormone laminar implants elicited the same anabolic
effects in rats as the daily injectable form but without theNutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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associated problems such as renal toxicity and stress at the
injection site [46]. Furthermore, a single injection of
microencapsulated slow release recombinant human
growth hormone in immunosuppressed Hpx rats showed
greater long term pharmacological effects such as
increased growth rate and IGF-I levels in comparison with
daily injections for 35 days [47]. Moreover, there were no
differences in the anabolic effects of either rodent or
human growth hormone administration in rats [48]. In
our study we utilized GHi was injected daily just under the
skin (SC) at the back of the neck. The half-life of this type
of growth hormone is 124 minutes when utilized in
rodents [49]. We have conducted three prior studies of
suboptimal nutrition in our laboratory [5,20,21] utilizing
the same type of growth hormone. We always observed
increased growth and body weight gain without any
apparent health problems. It is possible that the short half
life of this product prevented any toxic effects in our rats.
Conclusion
Our results demonstrate that beneficial effects of GHi are
obtained during mild energy restriction. Moreover, mild
Zn restriction does not have negative effects on body
weight gain. Growth hormone therapy does promote
body weight gain despite mild energy and Zn restrictions
without any apparent effects on metabolic rate and phys-
ical activity. Finally, no additive effects between Zn and
energy are observed during mild combined restriction of
energy and Zn intakes.
Materials and methods
Forty pre-pubertal two week old male Sprague-Dawley
rats were studied over a four-week period at the Miami
Children's Hospital Research Institute in Miami Florida.
The animals were individually housed in wire-bottom
stainless steel cages avoiding coprophagia. The experi-
mental design is depicted in Figure 1. Rats were main-
tained on a 12 hour light/dark cycle beginning at 7:00
AM. Four groups of 10 Sprague-Dawley male rats were fed
four different balanced purified 1:1 carbohydrate to fat
diets (Purina Mills Test Diets, Richmond, IN) adjusted for
energy and Zn according to the following [50]:
1) Diet A – 100% of all nutrients, fed ad-libitum
2) Diet B – 70% energy and 100% of all the nutrients,
pair-fed with rats in group A
3) Diet C – 100% energy and all the nutrients but 70% Zn,
fed ad-libitum
4) Diet D – 70% of both energy and Zn, and 100% of the
rest of the nutrients, pair-fed with rats in group C
Purified diets were used in order to precisely control the
amount of nutrients and to eliminate the variability often
associated with commercial rat chows. The composition
of the experimental diets is shown in Table 1. The control
diet (Diet A) was formulated to contain all nutrients,
including vitamins and minerals, necessary for normal
growth in rats as defined by the National Research
Council [50]. The dietary guidelines for rodents were
based on rats consuming approximately 60 calories (15 g)
of commercial rat chow per day. The formulation of each
diet and the related modifications to the energy and Zn
levels for the restricted diets (Diets B and D) were based
on consumption of similar diets in three previous studies
of suboptimal nutrition [5,20,21].
The amount of both restricted diets (Diets B and D) fed
were based on the amount of control diets (Diets A and C)
consumed by pair-fed control rats. For example, the
amount of the restricted diet (Diet B) fed was based on the
consumption of the rats pair-fed the control diet (Diet A)
from the previous day. All nutrients, except energy, were
concentrated to compensate for the 30% reduction in
food intake. For the rats fed the diet containing adequate
energy but with reduced levels of dietary Zn (Diet C), the
Zn level was reduced to 8.1 mg/kg of diet, based on the Zn
requirements for adult rats (12 mg Zn/kg diet) as set by
the National Research Council [50,30]. Both adequate Zn
diets (Diets A and B) were formulated to contain 12 mg
Zn/kg of diet. The amount of Diet D fed, were both energy
and Zn were formulated at 70% of requirements, was
based on the previous days intake of rats pair-fed ade-
quate energy but with 70% of Zn requirements (Diet C).
One half of each group were administered a daily dose of
0.1 mg of GHi per 100 grams of body weight [20] (Soma-
tropin rDNA Origin, Humatrope, Eli Lilly & Co.
Indianapolis, IN) subcutaneously before 10:00 AM in the
morning, while the controls received a similar amount of
normal saline solution (NSS), the diluent for GHi.
The percentages of metabolisable energy from fat, carbo-
hydrate and protein were adapted from McCarger et al
[51] and approximated those of typical American diets.
The proximate analysis and macro-nutrient distribution is
shown in Table 2. Because the rats were provided excess
protein over the minimal requirement (15% for growth,
maintenance and breeding) in the ad-libitum diet (Table
2), it was not necessary to adjust crude protein content for
formulation of the restricted diets. All control and
restricted rats were consuming approximately 23 and 16%
protein, respectively. However, micronutrient levels were
maintained at adequate levels by increasing their concen-
tration in the restrictive diets. The percentage of alpha cel-
lulose was reduced to accommodate the increased
concentrations of micronutrient mixes (Table 1).Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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Experimental design and assays Figure 1
Experimental design and assays
Table 1: Composition of experimental diets
Energy/Zinc (%)1 100/100 70/100 100/70 70/70
Casein (92% purity) 24.8 24.8 24.8 24.8
DL-Methionine 0.22 0.34 0.22 0.34
Sucrose 15.00 15.00 15.00 15.00
Dextrin 22.70 22.70 22.70 22.70
Lard 8.37 8.37 8.37 8.37
Corn Oil 8.37 8.37 8.37 8.37
Choline bitartrate 0.15 0.22 0.15 0.22
Vitamin mix 0.74 1.12 0.74 1.12
Mineral mix 2.60 3.79 2.60 3.79
Alpha cellulose 17.09 15.33 17.09 15.33
Zinc Carbonate (52% 
purity)
0.0023 0.0023 0.00162 0.00162
1 = The amount of each ingredient is the percentage of the total dietNutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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Rats consumed deionized water ad-libitum. Furthermore,
this water was used for food preparation. The deionized
water was found to be zinc free by the Miami-Dade
Department of Public Health utilizing graphic furnace
atomic absorption spectroscopy. The lower limit of detec-
tion was 0.05 ug/l (Trace Analytical Laboratories, Muske-
gon MI). Weight and estimate of food intake were
obtained for each rat daily in the morning prior to GHi
and NSS injections. Food fed to the restricted rats was cal-
culated based on the amount of food consumed by the
respective pair mates in the ad-libitum fed groups. The
amount of food given to the rats paired at 70% of energy
restriction was calculated as follows: [(food consumed by
the ad-libitum rat during the previous day/weight of this
rat in the previous day) × (0.7) × (Current weight of the
rat for which the food is estimated)]. Weight and food
intake were recorded daily. After four weeks of the experi-
mental period all rats were anesthetized with Nembutal
(30–50 g/kg BW) and sacrificed by cardiac puncture in the
morning at the same time of recording of body weight and
GHi and NSS injections. Furthermore, all rats were fasted
that same morning to prevent any effects of absorbed
nutrients on hormonal assays. The last injection of GHi
and NSS occurred the prior morning thus eliminating any
effect of these injections on the results obtained from
blood samples. Blood samples for serum IGF-I, IGFBP-3
and Insulin were drawn and carcasses were frozen at -20
degrees C for future measurements of body composition
using Folch's analysis method for fat extraction [52]. Sam-
ples were not frozen more than one week prior to analysis.
All experimental protocols were reviewed and approved
by the Miami Children's Hospital Institutional Animal
Care and Use Committee.
Hormonal assays
Blood samples were spun and corresponding serum sam-
ples fractionated in aliquots. All serum samples were fro-
zen at -20 degrees C for no more than one week for
subsequent analysis. Each hormonal assay was run simul-
taneously on all samples.
Serum IGF-I concentration was measured by double anti-
body radioimmunoassay (RIA). Samples were prepared
by acid-ethanol extraction followed by cryoprecipitation
using a kit from Nichols Institute Diagnostics (San Juan
Capistrano, CA). This procedure minimized the interfer-
ence of IGF-I binding proteins at the time of the assay. The
standard curve was linear between 5 and 600 ng/ml with
a Coefficient of Variation of 3%. The sensitivity of this
radioimmunoassay was equal to 0.06 ng/ml. The intra-
assay coefficient of variation was equal to 2.4 and 3% at
concentrations of 0.5 and 0.9 ng/ml, respectively. The
inter-assay variance at 0.5 ng/ml and 0.8 ng/ml were equal
to 5.2 and 8.4%, respectively.
Serum IGFBP-3 level was measured by double antibody
RIA using a kit from Diagnostic Systems Laboratories, Inc.
(Webster, TX). The standard curve was linear between 2.5
and 100 ng/ml with a Coefficient of Variation of 3.2%.
The minimum detection limit was 0.5 ng/ml. The intra-
assay precision at 82.7, 27.5 and 7.3 ng/ml was 1.8, 3.2
and 4%, respectively. The inter-assay precision at 80, 21,
and 8 ng/ml was 1.9, 0.5 and 0.6%, respectively.
Serum Insulin level was measured by double antibody
RIA using a kit from ICN Pharmaceuticals, Inc. (Costa
Mesa, CA). The standard curve was linear between 5.5 and
310 mIU/ml with a Coefficient of Variation of 8%. The
sensitivity was 1.5 mIU/ml. The intra-assay variation were
determined for the following concentrations at 18.2, 36.5
Table 2: Proximate analysis of experimental diets
Energy/Zn(%) 100/100 70/100 100/70 70/70
Percentage macronutrient composition
Protein 22.78 15.95 22.78 15.95
Fat 38.38 38.38 38.38 38.38
Carbohydrate 37.70 26.39 37.70 26.39
Percentage contribution to energy
Protein 23.21 23.21 23.21 23.21
Fat 38.38 38.38 38.38 38.38
Carbohydrate 38.41 38.41 38.41 38.41
Percentage contribution to total intake
Energy 100 70 100 70
Zinc 100 100 70 70Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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and 91.5 mIU/ml and were 8.2, 4.2 and 5.4%,
respectively.
Metabolic assessment
Each rat was weighed and had 24-hour energy expendi-
ture (24-h EE; kcal/100 g BW), respiratory quotient
(RQ;VCO2/VO2) and an index of physical activity (PA;
oscillations/min/kg BW) measured in the Enhanced Met-
abolic Testing Activity Chamber (EMTAC). The main ana-
lytical unit of this instrument was developed to be
suitable for various applications in both humans and ani-
mals for comprehensive measurements of energy expend-
iture and physical activity [53,54]. For this study, the
EMTAC was retrofitted with a 72 liter plexiglass rodent
enclosure (Figure 2). This maintained the rodent's envi-
ronment thus eliminating the need to acclimate the rat to
a different metabolic chamber. Measurements of 24-h
energy expenditure and the index of physical activity con-
sisted of first placing the rat, along with the appropriate
experimental diet and deionized water, in a Nalgene met-
abolic cage. This cage was inserted into the EMTAC rodent
enclosure at 10:00 AM and energy expenditure determina-
tions were done by measurement of oxygen and carbon
dioxide exchange within the enclosure. The same light/
dark cycle used in the rodent facility was maintained. The
physical activity index was obtained by placing the entire
rodent enclosure on a balance that was connected to the
EMTAC unit. The oscillations in weight (g), generated by
movements of the rat, were read from the balance and uti-
lized to calculate an index of physical activity expressed as
oscillations in weight (g)/minute/kg body weight of the
rat. For these calculations the software calculated the body
weight of the rat in kilograms. The formulas used to calcu-
late energy expenditure and physical activity index using
the EMTAC have been described previously [53,54,34].
Energy expenditure was expressed per 100 g body weight
to factor out the effects of body weight changes on meta-
bolic rate.
Body composition analysis
Body composition analysis included total body water con-
tent (TBW), fat-free mass (FFM) and body fat (BF) deter-
minations. This procedure comprised three different
steps: 1) carcass homogenization, 2) water content and
dry weight determinations and 3) fat content determina-
tion by fat extraction.
The first step consisted of autoclaving each animal carcass
for one hour at 15.3 psi and 120 degrees C in order to
facilitate carcass homogenization. Each carcass was indi-
vidually placed in a large beaker with covered tops with a
known amount of distilled water. Each carcass was
allowed to cool off overnight and then homogenized
using a PowerGen700 blender. Triplicate aliquots of the
homogenate were frozen at -20 degrees C for subsequent
analysis. The chemical analysis of each homogenized car-
cass was carried out in triplicate and mean values of these
triplicate samples were taken as ultimate values of TBW
and BF content. The second step consisted of drying sam-
ples overnight at -380 mm Hg at 40 degrees C in a vacuum
oven to determine water content. The difference between
petri dish weight before and after overnight water extrac-
tion was considered as the dry weight of the carcass
sample.
The third step consisted of determining BF content by a
modified Folch's method [52] for fat extraction. All sam-
ples were analyzed following this technique's protocol
which comprised two different procedures. In the first
procedure, lipids were extracted from the homogenate by
adding a 2:1 methanol-chloroform mixture. Each sample
was separately filtered and a 5-fold volume of distilled
water was added to separate lipids from non-lipid
Rodent EMTAC enclosure that was used to obtain measure- ments of 24-hour energy expenditure and the index of physi- cal activity Figure 2
Rodent EMTAC enclosure that was used to obtain measure-
ments of 24-hour energy expenditure and the index of physi-
cal activity. Note the placement of the enclosure on the 
balance for measurement of the index of physical activity.Nutrition & Metabolism 2005, 2:10 http://www.nutritionandmetabolism.com/content/2/1/10
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substances. This mixture was centrifuged for 15 minutes at
3000 rpm at three degrees C, producing three separated
layers. The clear upper layer contained a mixture of meth-
anol and water. The fluffy middle layer contained non-
lipid substances and the clear lower layer contained a mix-
ture of tissue lipids and chloroform. This bottom layer
containing lipids and chloroform was isolated by remov-
ing the upper and the middle layers by vacuum aspiration.
During the second procedure, all samples containing only
the remaining bottom layer were dried overnight at -380
mm Hg at 40 degrees C in a vacuum oven, thus allowing
chloroform evaporation and subsequent lipid separation.
The difference between the tubes weight before and after
fat extraction was taken as grams of fat content [55].
Fat-free mass was calculated by subtracting BF percentage
from total body mass and expressed as percentage of total
body mass.
Statistical analysis
The effects of GHi on body weight gain, FFM, BF, TBW,
Insulin, IGF-I and IGPBP-3 within each dietary treatment
group (GHi vs. NSS) were determined by Independent t-
test. A similar analysis was utilized to compare changes in
24-hour energy expenditure and physical activity between
all ad-libitum and energy restricted (70%) rats. The inter-
action between diet and hormone treatments across all
diet groups was determined by 2-way ANOVA with least
significant difference (LSD). Simple size was based on the
results of three prior studies of suboptimal nutrition in
rats [5,20,21]. In these studies five rats per individual
treatment was enough to detect significant differences in
body weight gain, the major parameter studied, at p <
0.05. The rest of the parameters were measured in order to
explain the changes of body weight gain for each treat-
ment group. All data are presented as mean ± standard
deviation (SD) unless otherwise noted.
Abbreviations
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24-h EE = Twenty-four hour energy expenditure
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